SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining substantial attention as its stock consistently trades above a critical threshold, signaling increased institutional interest and strong confidence in its advanced-stage pipeline. The community is actively discussing the highly promising efficacy signals from its GPS immunotherapy trial for AML, which is reportedly extending patient survival far beyond historical expectations and positioning the asset for a significant revaluation or potential buyout. This robust sentiment, amplified by considerable short interest and high borrow fees, is fueling widespread anticipation for a potential short and gamma squeeze.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain and as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is experiencing significant community interest, largely driven by its availability on Robinhood and increasing anticipation for the Goliath Mainnet. Investors are actively discussing its potential for institutional adoption and enhanced real-world utility, with many viewing the Binance Futures delisting as a positive catalyst for organic price discovery. The broader crypto market's altcoin season narrative also contributes to bullish sentiment around XCN.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid a strong market rally, fueled by positive reactions to US geopolitical action in Venezuela impacting oil markets and continued optimism surrounding advancements from major AI chipmakers. While many investors see this as a sustainable climb, others express concern about market fragility and institutional selling masking underlying risks.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance (PSKY) is heavily discussed amid its persistent pursuit of Warner Bros. Discovery, with a significant financing guarantee from a key backer recently intensifying the acquisition saga. The community is actively debating the merits of PSKY's substantial all-cash bid versus a competing offer, alongside the WBD board's perceived resistance and fiduciary duties. Separately, investors are excited about the upcoming integration of major sports content onto Paramount+, viewing it as a strong move to enhance its streaming competitiveness.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing heightened scrutiny as NVIDIA significantly expands into autonomous driving and humanoid robotics, directly challenging the core growth narratives underpinning TSLA's valuation. Community discussion is sharply divided, with bulls emphasizing Tesla's long-term AI and energy potential, while bears highlight intensified competition, concerns over EV sales, unfulfilled FSD promises, and a recent reiteration of a "Sell" rating by UBS.

Momentus, Inc. engages in the provision of in-space infrastructure services. It offers space transportation and in-orbit servicing. The company was founded by Mikhail Kokorich in 2017 and is headquartered in Santa Jose, CA.

Momentus Inc - Ordinary Shares - Class A

Momentus is seeing intense trading activity following news of its innovative 3D-printed fuel tank for an upcoming space mission, fueling speculation of a potential short squeeze given its high short interest. While this development has energized bullish sentiment around its space technology, a recent private placement has introduced significant volatility and community discussion regarding potential dilution. Investors are keenly observing if its advancements can overcome financing concerns within the currently active space sector.

Aeva Technologies, Inc. develops sensing paradigm for autonomous vehicles and robotics. The firm offers drones, robotics, vehicle technology, and virtual and augmented reality products. The company was founded by Soroush Salehian Dardashti and Mina Rezk in 2017 and is headquartered in Mountain View, CA.

Aeva Technologies Inc

Aeva Technologies is prominently trending after announcing a partnership with NVIDIA to integrate its 4D LiDAR as a reference sensor within the NVIDIA DRIVE Hyperion platform ecosystem. This collaboration is widely regarded by the community as a significant validation, fueling discussions about strong market momentum and Aeva's strengthening position in the autonomous vehicle and broader LiDAR sectors.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPDR S&P 500 ETF Trust (SPY) is trending as market participants react to recent geopolitical developments surrounding Venezuela, with many attributing recent market rallies to the situation. While some in the community cheer the market's "ATH incoming" momentum and anticipate further gains from upcoming earnings and AI sector strength, others express skepticism, warning of a "bull trap" amidst concerns over dollar stability and underlying economic fragilities. The ongoing conversation highlights a stark divide between those expecting new all-time highs and those bracing for a potential correction.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is experiencing a significant surge, driven by a strong technical breakout from a multi-week wedge and reclaiming its 50-day moving average on increased volume. The community is actively discussing its potential for a major upward move, fueled by expectations of S&P 500 inclusion, upcoming earnings, and broader bullish sentiment within the diversified fintech and digital asset sectors.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending due to its announced strategic collaboration with OpenAI, integrating advanced AI models into its Athena marketing platform. The community is buzzing with excitement, viewing this partnership as a significant catalyst that underscores Zeta's undervalued status and potential for substantial growth in the AI-driven marketing technology sector, with many anticipating future announcements at CES.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company’s recently filed 10-Q filing satisfied Nasdaq’s quarterly reporting requirement.</li><li>The company failed to report its results for the quarter ended Sept. 30 in a timely manner, resulting in noncompliance with Nasdaq's Listing Rules.</li><li>The company filed its third quarter earnings report last week, posting a 28% jump in revenue for the period.</li></ul>Laser Photonics shares (<a href="https://stocktwits.com/symbol/LASE">LASE</a>) jumped more than 3% in premarket trading on Wednesday after it regained compliance with Nasdaq listing rule 5250(c)(1) regarding the timely filing of periodic reports.The Nasdaq Stock Market confirmed that the company's December 23 filing of its Form 10-Q for the quarter ended September 30, 2025, satisfied the quarterly reporting requirement. Nasdaq has closed the related compliance matter.The company received a notice from Nasdaq’s listing qualifications department in November stating that, because it had not received Laser Photonics’ Form 10-Q for the period ended September 30, 2025, it does not comply with Nasdaq's Listing Rules for continued listing.Nasdaq had stated that the company has until January 19, 2026, to submit a plan to regain compliance with respect to the delinquent report.Nasdaq may grant an exception to allow the company to regain compliance for up to a maximum of 180 calendar days from the Form 10-Q due date.&nbsp;<h2 class="st-heading-2">Q3 Results</h2>The company last week filed its third quarter (Q3) earnings report, which showed a 28% jump in total revenue to $0.9 million, up from $0.7 million the year-ago period.&nbsp;"Our Q3 report was impacted by a number of expense items and when combined with acquiring Beamer, caused us to be late with our quarterly filing. As this is now resolved, we expect to be back in compliance with Nasdaq imminently,” Carlos Sardinas, Chief Financial Officer of Laser Photonics, said.&nbsp;The Orlando-based company develops industrial laser systems for cleaning and material processing applications. The company has expanded its operations through acquisitions of Beamer Laser Systems and Control Micro Systems, broadening its capabilities into pharmaceutical and semiconductor manufacturing markets.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around LASE trended in “bearish’ territory amid “low” message volumes.&nbsp;<figure class="image"><img style="aspect-ratio:776/74;" src="https://news.stocktwits-cdn.com/LASE_PNG_3aa61b8267.webp" alt="Retail sentiment around LASE trended in “bearish’ territory amid “low” message volumes. " width="776" height="74"></figure>Shares in Laser Photonics have fallen 61% so far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Blue laser light shines in a part of an optical clock in a laboratory at the Physikalisch-Technische Bundesanstalt (PTB) in Braunschweig, Germany. (Photo by Julian Stratenschulte/picture alliance via Getty Images)

What’s Behind Laser Photonics' Stock Rise Today?

After months of regulatory scrutiny, Laser Photonics regained Nasdaq compliance. 

Equity

Laser Photonics (NASDAQ:LASE) Announces Quarterly Earnings Results

Laser Photonics (NASDAQ:LASE - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($1.09) earnings per share for the quarter. The company had revenue of $0.92 million...

Laser Photonics (NASDAQ:LASE) Stock Price Down 2.9% - Here's What Happened

Laser Photonics (NASDAQ:LASE) Shares Down 2.9% - Time to Sell...

Laser Photonics (NASDAQ:LASE) Trading Down 3.3% - Here's Why

Laser Photonics (NASDAQ:LASE) Trading Down 3.3% - Time to Sell...

WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters.&nbsp;Our focus is on quality, liquid, growth-oriented, and under-followed companies in sectors actively drawing in capital such as AI, blockchain, biotech and consumer.&nbsp;This real-time news surveillance and targeting combined with our proprietary 5-point analysis, aids in uncovering stocks poised for powerful multi-day or multi-month moves—often long before Wall Street analysts catch on.&nbsp;Here’s what we’re keeping our eyes on:<h3>1. Purple Biotech (NASDAQ: PPBT)</h3>Background: Purple Biotech is a clinical-stage oncology company that aims to redefine cancer treatment through its innovative approaches targeting tumor immune evasion and drug resistance. Its lead product, CM24, is a first-in-class anti-CEACAM1 antibody being developed to treat pancreatic and other aggressive cancers. The oncology space, worth billions, continues to see intense investor interest, especially as companies explore biomarker-driven therapies.The News: Purple Biotech unveiled final Phase 2 results showing CM24 combined with nivolumab and chemotherapy significantly improved overall survival (OS) and progression-free survival (PFS) in pancreatic cancer patients with specific biomarkers. The data revealed a 79% reduction in death risk and a 5.1-month OS improvement, particularly in biomarker-enriched patient groups.What It Means: These results not only validate CM24’s potential but also position Purple Biotech to expand its pipeline into broader cancer applications. With a planned Phase 2b trial targeting high-CEACAM1 patients, the company is tapping into precision oncology—a sector that continues to draw investor enthusiasm due to its game-changing potential.Stock Reaction: PPBT skyrocketed 151%, reflecting the market’s recognition of this major milestone in the fight against pancreatic cancer.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_23_40_AM_19763a2e26.png" alt="Screenshot 2024-12-05 at 2.23.40 AM.png">&nbsp;<hr>&nbsp;<h3>2. Stereotaxis (NYSE: STXS)</h3>Background: Stereotaxis is at the forefront of surgical robotics, specializing in robotic magnetic navigation (RMN) systems for minimally invasive endovascular interventions. Its GenesisX system aims to improve precision, safety, and efficiency in procedures, a critical innovation as the global market for robotic-assisted surgeries is projected to grow at a double-digit CAGR over the next decade.The News: The GenesisX robotic system was showcased for the first time at the RSNA 2024 Annual Meeting, in collaboration with Neusoft Medical Systems. The partnership aligns GenesisX with advanced imaging technologies, offering enhanced capabilities for healthcare providers worldwide.What It Means: The exposure at RSNA, one of the largest radiology conferences globally, strengthens Stereotaxis' visibility and positions the GenesisX as a next-generation tool for minimally invasive surgeries. This partnership could unlock new revenue streams as the healthcare sector increasingly adopts robotic solutions.Stock Reaction: STXS edged up 4.18%, with investors optimistic about the long-term implications of the GenesisX system.Stocktwits.com Sentiment &amp; Popularity:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_25_09_AM_6fecf5b145.png" alt="Screenshot 2024-12-05 at 2.25.09 AM.png">&nbsp;<hr>&nbsp;<h3>3. Delcath Systems (NASDAQ: DCTH)</h3>Background: Delcath Systems focuses on innovative therapies for primary and metastatic liver cancers. Its flagship product, HEPZATO KIT™, offers a unique approach to delivering high-dose chemotherapy directly to the liver while minimizing systemic exposure. This precision is critical for targeting liver-dominant diseases—a market that represents tens of thousands of patients annually.The News: The FDA has cleared Delcath’s Phase 2 trial of HEPZATO in liver-dominant metastatic colorectal cancer. The study will compare HEPZATO plus standard chemotherapy with chemotherapy alone, aiming to validate its safety and efficacy in this high-need population.What It Means: HEPZATO has already shown promise in metastatic uveal melanoma, and this expansion could significantly broaden its market reach. The ability to address liver-dominant cancers positions Delcath as a potential leader in a niche but high-value market.Stock Reaction: DCTH rose 6.4% on the day, continuing its strong performance following a 203% year-to-date rally.&nbsp;&nbsp;<hr>&nbsp;<h3>4. BrainStorm Cell Therapeutics (NASDAQ: BCLI)</h3>Background: BrainStorm is a pioneering biotech company developing autologous adult stem cell therapies for neurodegenerative diseases like ALS and progressive MS. Its lead candidate, NurOwn®, is designed to deliver neurotrophic factors directly to damaged neurons, potentially altering the course of these debilitating diseases. With few effective therapies for ALS, the market is ripe for disruptive innovation.The News: BrainStorm announced a December 11 webinar featuring updates on its Phase 3b trial of NurOwn, aimed at refining the therapy’s efficacy for FDA approval. This comes as the company prepares for a pivotal registrational trial.What It Means: If successful, NurOwn could be the first significant breakthrough for ALS in years, addressing an unmet medical need in a multibillion-dollar market. The company’s focus on early-stage ALS patients may improve trial outcomes and strengthen its case for regulatory approval.Stock Reaction: BCLI dipped 2.66%, reflecting cautious investor sentiment as the market awaits trial data.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_26_15_AM_28681ca8de.png" alt="Screenshot 2024-12-05 at 2.26.15 AM.png">&nbsp;<hr>&nbsp;<h3>5. DMG Blockchain Solutions (OTCQB: DMGGF)</h3>Background: DMG Blockchain integrates Bitcoin mining with sustainability and AI-driven data centers. Its Terra Pool initiative is designed to create a carbon-neutral Bitcoin mining ecosystem, catering to ESG-conscious investors and industries. With institutional adoption of Bitcoin accelerating, DMG’s dual focus on growth and environmental responsibility makes it a standout.The News: DMG reported November mining results of 32 BTC, an increased hashrate of 1.66 EH/s, and significant insider purchases by its CEO and COO. The company also secured $17.3 million to fund growth initiatives, including AI and blockchain infrastructure.What It Means: The raised capital and insider purchases signal confidence in DMG’s ability to scale operations and align with Bitcoin’s anticipated market growth. The focus on sustainability could attract institutional players prioritizing ESG compliance.Stock Reaction: DMGI remained stable dipping just slightly, with the market digesting the long-term growth potential from recent investments.&nbsp;<hr>&nbsp;<h3>6. BriaCell Therapeutics (NASDAQ: BCTX)</h3>Background: BriaCell specializes in novel immunotherapies targeting advanced breast cancer. Its lead therapy, Bria-IMT™, is designed to boost the immune system's response against tumors. With metastatic breast cancer affecting over 2 million women globally, there’s an urgent need for effective treatments.The News: BriaCell’s pivotal Phase 3 study of Bria-IMT received a positive safety review from the DSMB, allowing the trial to proceed without changes. The trial is being conducted under the FDA’s Fast Track Designation.What It Means: The DSMB’s approval reinforces Bria-IMT’s safety and paves the way for the company to potentially deliver a game-changing therapy for metastatic breast cancer patients. The Fast Track Designation further emphasizes its potential impact.Stock Reaction: BCTX shares soared 13%, reflecting growing investor confidence in the company’s clinical progress.Rumours from Twitter:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_27_31_AM_e685b0a306.png" alt="Screenshot 2024-12-05 at 2.27.31 AM.png">&nbsp;&nbsp;<h3>7. Laser Photonics Corporation (NASDAQ: LASE)</h3>Background: Laser Photonics Corporation specializes in industrial laser systems, providing innovative solutions for cleaning, material processing, and now pharmaceuticals. With its recent acquisition of Control Micro Systems, Inc., the company is expanding into new sectors, including the fast-growing pharmaceutical and semiconductor industries. The industrial laser market, driven by advances in automation and precision engineering, is projected to exceed $10 billion by 2030, making it a hotbed for innovation.The News: Laser Photonics announced the successful installation of a state-of-the-art pill drilling system at a customer’s facility. The system, a Class I automated CO2 laser with advanced fume extraction and machine vision inspection, is designed to streamline pill production processes. This system also doubles as an anti-counterfeiting solution, addressing critical challenges in the pharmaceutical supply chain.What It Means: This installation signifies Laser Photonics’ pivot into high-demand verticals like pharmaceuticals. By integrating advanced laser technology with automated inspection, the company is positioning itself as a key supplier in a market prioritizing efficiency, precision, and security.Stock Reaction: LASE shares declined 6.40%, reflecting broader market volatility rather than company-specific concerns. Investors appear cautiously optimistic about the company's potential in its newly targeted markets.&nbsp;Also Read:<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/why-this-small-biotech-stock-could-be-primed-for-a-breakout/">&nbsp;Why This Small Biotech Stock Could Be Primed for a Breakout</a>Be the First to Know:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like&nbsp;AST SpaceMobile (NASDAQ: ASTS), which shot up&nbsp;+533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a long or short position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

News Movers: Yesterday’s Hottest News That Could Move the Needle Today

Your Only Digest of Market-Moving News and Rumours From High-Growth, Small Cap Stocks

Laser Photonics Corp. engages in the business of manufacturing and research and development of industrial laser technologies and systems. The firm also offers operations that allow the customers to reduce development and advanced laser equipment manufacturing time, offer better prices, control quality, and protect the proprietary knowhow and technology compared to other laser cleaning companies and companies with competing technologies. The company was founded on November 8, 2019 and is headquartered in Orlando, FL.

Laser Photonics Corp

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

LASE
Laser Photonics Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results:

Historical Earnings

Latest LASE News

LASELaser Photonics Corp